-
Published 9/27/2025
Campbell PM, Ess GJ, Lale A, Talaat KR, Barnett ED, Pelton SI, Schlaudecker EP, Staat M, Stockwell MS, LaRussa PS, Walter EB, Smith MJ, Halsey NA, Klein NP, McNeil MM, Broder KR, Shimabukuro TT, Crist MB, Fairlie TA, Sharma S, Creech CB, Edwards KM. Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews. Vaccine. 2025 Oct 24; 65:127781. PMID: 41016231.
-
Published 7/18/2025
Lapidot R, Averin A, Weycker D, Huang L, Vietri J, Arguedas A, Cane A, Lonshteyn A, Rozenbaum MH, Pelton SI. Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status. Front Public Health. 2025; 13:1558157. PMID: 40756406.
-
Published 7/12/2025
Imran M, Chastek B, Bancroft T, Webb N, Pelton SI, Haag MDM, McGovern I. Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season. Int J Infect Dis. 2025 Oct; 159:107983. PMID: 40659177.
-
Published 5/2/2025
Zhang Z, Yildirim M, Keskinocak P, Dasthagirisaheb YBS, Hinderstein S, Tran K, Crockett M, Burns M, Johnson H, Popstefanija M, Madoff LC, Pelton SI, Yildirim I. Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis. Vaccine. 2025 May 22; 56:127193. PMID: 40318350.
-
Published 4/3/2025
Averin A, Weycker D, Lapidot R, Rozenbaum MH, Huang L, Vietri J, Arguedas Mohs A, Cane A, Lonshteyn A, Pelton SI. Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children. J Med Econ. 2025 Dec; 28(1):517-523. PMID: 40152182.